

Under the aegis of



D&CVD



3rd EDITION Update on Diabetes and CVD

Meeting in cooperation
between:

D&CVD Study Group

(Reference Study Group of EASD)
IRCCS MultiMedica, Milan

16th-17th January 2026

PAVIA
Collegio Ghislieri



SCIENTIFIC RATIONALE

The presence of hyperglycemia associated with the well-known risk factors of metabolic syndrome and diabetes itself predispose to important cardiovascular complications which have a strong impact on the quality of life of the individual and on the community in general, also from an economic point of view. The cardio-vascular-renal complications of diabetes still represent the major cause of mortality and disability of people affected by it, resulting in hospital admission in over 75% of cases.

In recent years, we have available different categories of drugs with proven effects of positive action on the significant reduction of cardiovascular and renal events; recommended consequently in national and international guidelines, as early use for the treatment of diabetes.

It is of the utmost importance to assess cardiovascular risk in individuals with diabetes who do not yet have clinical evidence of cardiovascular disease, in order to identify those at the highest risk, in which maximum prevention must be immediately activated, correcting lifestyles and implementing the most appropriate therapy. From stratification of cardiovascular risk to screening, diagnosis and treatment. The new Guidelines for cardiovascular diseases, in people with diabetes, of the European Society of Cardiology (ESC), evaluate and summarize the available scientific evidence, with the aim of supporting health professionals in proposing the best diagnostic and therapeutic approach.

The purpose, therefore, of this course is to deepen and update the current knowledge of prevention of diabetes complications, with maximum interactivity between cardiologists and diabetologists; deepening the epidemiology and pathogenesis of renal and cardiovascular diseases, the possible mechanisms of action in the demonstrated prevention, the comparison of the different therapeutic approaches and the possible advantages of an early and more generalized use.



3rd EDITION

Update on Diabetes and CVD

Meeting in cooperation between:
D&CVD Study Group
(Reference Study Group of EASD)
IRCCS MultiMedica, Milan

FACULTY

Lucio Amoresano Monza (IT)
Angelo Avogaro Padova (IT)
Tadej Battelino Ljubljana (SI)
Irene Bernardi Monza (IT)
Cesare Celeste Federico Berra Milan (IT)
Federico Bertuzzi Milan (IT)
Antonio Carlo Bossi Bergamo (IT)
Riccardo Candido Trieste (IT)
Alberico Luigi Catapano Milan (IT)
Daniela Ceccarelli Ceccarelli Pesaro (IT)
Antonio Ceriello Milan (IT)
Nadia Cerutti Pavia (IT)
Stefano Ciardullo Monza (IT)
Caterina Conte Rome (IT)
Francesco Cosentino Stockholm (SE)

Nicola Cosentino Milan (IT)
Gian Marco Dacquino Milan (IT)
Giulia Ferrannini Stockholm (SE)
Amalia Gastaldelli Siena (IT)
Andrea Giaccari Rome (IT)
Francesco Giorgino Bari (IT)
Per-Henrik Groop Helsinki (FI)
Ernesto Maddaloni Rome (IT)
Roberto Manfrini Milan (IT)
Barbara McGowan London (UK)
Marco Mirani Milan (IT)
Laura Molteni Como (IT)
Paola Muti Milan (IT)
Emanuela Orsi Milan (IT)
Dimitrios Papamargaritis Leicester (UK)

Scientific Directors
Cesare Celeste Federico Berra
Antonio Ceriello
Bruno Solerte

Roberto Pontremoli Genoa (IT)
Francesco Pratichizzo Milan (IT)
Giuseppe Pugliese Rome (IT)
Veronica Resi Milan (IT)
Cristina Romano Varese (IT)
Giuseppe Rosano London (UK)
Antonio Rossi Milan (IT)
Giuseppina Russo Messina (IT)
Bruno Solerte Pavia (IT)
Roberto Trevisan Bergamo (IT)
Luc Van Gaal Antwerp (BE)
Roberto Vettor Padua (IT)
Cristiana Vitale Rome (IT)
Maurizio Volterrani Rome (IT)
Michal Vrablik Prague (CZ)

DAY 1: JANUARY 16th 2026

09.00-09.30 **Welcome and Introduction to The Meeting**

Antonio Ceriello (Chair D&CVD Study Group)

Paola Muti (Scientific Director IRCCS Multimedia)

Bruno Solerte (University of Pavia)

SESSION I:

09.30-10.15 **NEW GUIDELINES FOR THE MANAGEMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES**

Chairmen: Andrea Giaccari, Veronica Resi

09.30-09.45 **IDF Global Recommendations for Type 2 management** - Antonio Ceriello

09.45-10.00 **ADA/EASD 2026** - Francesco Giorgino

10.00-10.15 **Discussion**

SESSION II:

10.15-11.15 **CARDIO-RENAL DISEASE IN TYPE 1 DIABETES**

Chairmen: Salvatore De Cosmo, Cristina Romano

10.15-10.30 **CVD in type 1 diabetes** - Francesco Cosentino

10.30-10.45 **CKD in type 1 diabetes** - Per-Henrik Groop

10.45-11.00 **What can we translate from type 2 to type 1 as therapeutic perspective?**

Roberto Pontremoli

11.00-11.15 **Discussion**

11.15-11.45 **Coffee Break**

SESSION III:

11.45-12.45 **WEIGHT MANAGEMENT AND POSSIBLE SIDE EFFECTS**

Chairmen: Marco Mirani, Roberto Vettor

11.45-12.00 **Weight management in obesity**

Luc Van Gaal

12.00-12.15 **Weight management in type 2 diabetes: new perspective with the role of double agonism GIP/GLP1** - Caterina Conte

12.15-12.30 **Weight management in type 1 diabetes**

Ernesto Maddaloni

12.30-12.45 **Discussion**

12.45-14.00 **Lunch**

SESSION IV:

14.00-15.00 **CARDIO-RENAL DISEASE IN TYPE 2 DIABETES**

Chairmen: Lucio Amoresano, Giuseppe Pugliese

14.00-14.15 **How cardiologists can manage excess body weight and related cardiovascular risk**

Giuseppe Rosano

14.15-14.30 **The link between heart failure and kidney disease: how to face diabetes?**

A cardiologist point of view - Maurizio Volterrani

14.30-14.45 **The link between heart failure and kidney disease: how to face diabetes?**

A diabetologist point of view - Angelo Avogaro

14.45-15.00 **Discussion**

15.00-16.00 **LECTURES**

Chairmen: Antonio Ceriello, Bruno Solerte

15.00-15.30 **The reality of diabetes remission**

Dimitrios Papamargaritis

15.30-16.00 **The link between diabetes, cancer and CVD**

Paola Muti

SESSIONE V:

16.00-17.00 NEW RISK FACTORS FOR CVD

Chairmen: Nicola Cosentino, Roberto Manfrini

16.00-16.15 Emerging role of micro and nano-plastics in CVD - Francesco Prattichizzo

16.15-16.30 MASLD/NASH and CVD - Amalia Gastaldelli

16.30-16.45 Experience from EUROASPIRE

Giulia Ferrannini

16.45-17.00 360° diabete care: SGLT2i for Holistic Diabetes

Prevention Cesare Berra

17.00-17.15 Discussion

End of day one

DAY 2: JANUARY 17th 2026

SESSIONE VI:

09.00-10.00 WHAT'S NEW ON DEVICES AND MONITORING IN TYPE 2 DIABETES

Chairmen: Stefano Ciardullo, Emanuela Orsi

09.00-09.15 How can CGM help? - Tadej Battelino

09.15-09.30 Platforms and devices: how can help in type 2 diabetes - Antonio Rossi

09.30-09.45 Adherence and technology: new possibility for old problems - Federico Bertuzzi

09.45-10.00 Discussion

SESSIONE VII:

10.00-11.00 NEW INSIDE FOR OLD PROBLEM

Chairmen: Riccardo Candido, Nadia Cerutti

10.00-10.20 Autophagy as a potential target for drug repurposing in age-associated metabolic disorders - Daniela Ceccarelli Ceccarelli

10.20-10.35 10 years of CVOT with GLP1-RA: still new? Cesare Berra

10.35-10.50 Oral GLP1: an update - Irene Bernardi

10.50-11.00 Discussion

11.00-11.30 Coffee Break

SESSIONE VIII:

11.30-12.30 DIABETES AND LIPIDS

Chairmen: Alberico Catapano, Laura Molteni

11.30-11.45 Dyslipidemia in patients with diabetes: what's new in the EAS/ESC 2025 guidelines Michal Vrablik

11.45-12.00 iPCSK9 bempedoic acid and cardiovascular risk control in patients at high risk: Ldl-C Target and role of statins - Gian Marco Dacquino

12.00-12.20 Diagnosis of vascular complication in Type 2 Cristiana Vitale

12.20-12.30 Discussion



SESSIONE IX:

12.30-13.30 NEW PERSPECTIVE

Chairmen: Antonio Bossi, Fabio Buzzetti

12.30-12.45 New insulins - Roberto Trevisan

12.45-13.00 New therapies for the treatment of diabetes and obesity - Barbara McGowan

13.00-13.15 How early and how long should be the use of SGLT-2i and GLP1-RA? - Giuseppina Russo

13.15-13.30 Discussion

13.30-14.00 Closing remarks and take-home messages

Cesare Berra, Antonio Ceriello, Bruno Solerte

14.00 End of meeting

DATE: 16th-17th January 2026

VENUE: Collegio Ghislieri, Piazza Collegio Ghislieri, 5 - 27100 Pavia

ORGANIZING SECRETARIAT & CME PROVIDER - 181



ECM

QUALITY NETWORK

Assurance Points 181

APC

Management System

ISO 9001:2008

2023

www.apc.it

ID:

0000000009



certified

ecovadis

bronze

score

90

2023

www.ecovadis.org

in collaborazione con



empathy



APC

D&CVD



PROVIDER ECM STANDARD accreditato presso la Commissione Nazionale per la Formazione Continua in Medicina del Ministero della Salute con numero 181.

MIND DISTRICT - The Hive/H2 - Viale Decumano 36, 20157 Milan
giada.giuliani@dynamicom-education.it



The meeting will be accredited for the Italian physicians, in accordance with the existing national laws on CME.

Profession: Physicians and Nurse **Reserved to the following categories:** Metabolic Diseases and Diabetology, Endocrinology, Cardiology, Geriatrics, Internal Medicine. **Number of participants:** 200 **Training objective:** n. 3 **Assigned CME credits:** 8,4 **Official meeting languages:** Italian and English

REGISTRATION PROCEDURE

1. Go to the website www.dynamicomeducation.it.
2. If this is your first time accessing the platform, click on "Register" either in the top menu or at the bottom of the homepage, and complete the registration form with your personal details.
3. A confirmation email will be automatically sent to the address you provided.
4. Log in to the website using your personal credentials.
5. Click on the following link: <https://dynamicomeducation.it//event/update-on-diabetes-3rd-2026> or use the Search function to find the course titled "**UPDATE ON DIABETES AND CVD: 3RD EDITION MEETING IN COOPERATION BETWEEN**", then click the "Register" button.
6. After attending the in-person course, log in to the platform using your credentials and complete the evaluation questionnaires within 72 hours.

The ECM certificate will be available on the platform within 90 days after the end of the event, provided the questionnaire is passed and at least 90% of the scientific sessions have been attended.

For technical assistance, click the "Support" box on the homepage and fill out the form.

3RD EDITION Update on Diabetes and CVD

Meeting in cooperation between:
D&CVD Study Group
(Reference Study Group of EASD)
IRCCS MultiMedica, Milan

With the unconditional support of:

ASTRAZENECA

BAYER AG

BOEHRINGER INGELHEIM

LABORATORI GUIDOTTI

PIAM FARMACEUTICI

Thanks to the following sponsor companies for the printing:



Menarini, soluzioni per il domani

